FDA greenlights Revolution Medicines’ pancreatic cancer gamechanger
Summary:
FDA approved Rasonque (daraxonrasib), Revolution Medicines’ oral RAS inhibitor for metastatic pancreatic cancer. Median survival nearly doubled to 13.2 months versus 6.7 months on chemotherapy.
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
Summary:
AbbVie’s etentamig, a BCMA×CD3 bispecific T-cell engager, met both primary endpoints in Phase 3 CERVINO for relapsed myeloma — 74% response rate versus 45.7% on standard therapies.
Immune therapy engineered inside the body eases multiple sclerosis
Summary:
A modified virus engineered immune cells inside the body, easing multiple sclerosis in a small trial — in vivo cell therapy without ex vivo manufacturing.
Roche pays up to $1.53B for Simcere Zaiming’s tri-specific T-cell engager
Summary:
Roche took global rights to SIM0660, Simcere Zaiming’s first-in-class tri-specific antibody targeting CD3, CD79a and CD19, for $75 million upfront and $1.53 billion total.
BioNTech Halts Phase 2 Trial of Individualized mRNA Cancer Vaccine Autogene Cevumeran in Colorectal Cancer
Summary:
BioNTech and Genentech terminated the Phase 2 BNT122-01 trial of autogene cevumeran in resected colorectal cancer after the safety board flagged an overall survival imbalance.
